Summary

Food-contact packaging buyers should recheck existing approvals by matching each current commercial component to its exact phthalate identity, FDA authorization, permitted use conditions, analytical evidence, and change history. FDA’s May 27, 2026 evaluation proposed grouping DEHP, DCHP, DIOP, and DINP for a future cumulative risk assessment; it did not ban those substances, revoke their existing authorizations, or create new package-level limits. Approval should therefore not be withdrawn solely because a phthalate was evaluated, but it should remain open when a supplier cannot connect the formulation, cited 21 CFR provision or prior sanction, food type, temperature, contact duration, tested sample, and commercial production revision.

What Did FDA’s 2026 Evaluation Change?

The FDA’s current phthalates review covers eight ortho-phthalates authorized as plasticizers for specified food-contact uses:

• Diisononyl phthalate (DINP)
• Diisodecyl phthalate (DIDP)
• Di(2-ethylhexyl) phthalate (DEHP)
• Dicyclohexyl phthalate (DCHP)
• Butylphthalyl butyl glycolate (BPBG)
• Diethyl phthalate (DEP)
• Ethylphthalyl ethyl glycolate (EPEG)
• Diisooctyl phthalate (DIOP)

FDA found support for treating DEHP, DCHP, DIOP, and DINP as chemically or pharmacologically related substances in a future cumulative risk assessment. This grouping may affect how combined dietary exposure is assessed later.

It does not mean:

• the four substances are currently banned;
• their existing authorizations have been revoked;
• the other four substances have received unrestricted approval;
• a new concentration limit applies to finished packaging;
• every package containing one of the eight must automatically be reformulated.

The buyer’s immediate task is narrower: determine whether the existing approval file still describes the current package and whether the cited authorization actually covers its intended use.

Start With the Current Commercial Construction

Do not begin with a generic “phthalate-free” request. Begin by identifying where a plasticizer could exist in the commercial package.

Relevant components may include:

• flexible PVC films or sheets;
• closure-sealing gaskets and cap liners;
• seals and flexible molded components;
• adhesives and tie layers;
• polymeric coatings;
• lubricants associated with metallic packaging;
• plasticized labels or secondary components;
• other polymer additives introduced during compounding or conversion.

Build the following relationship for each component:

Packaging code → Construction revision → Component → Material grade → Plasticizer identity → Use level → Supplier/site → Authorization → Intended-use conditions

A declaration covering the main substrate does not automatically cover an adhesive, gasket, closure, or coating. A current declaration also cannot be applied retrospectively unless it identifies the formulations and supply periods covered.

Recheck the Exact Authorization, Not Just the Chemical Name

FDA authorizes food-contact substances according to identity, intended use, and conditions of use. Appearance in the FDA Inventory of Food Contact Substances Listed in 21 CFR does not create unrestricted authorization. The cited regulation must still be checked against the actual component and application.

The following map is a first screening step, not a substitute for reviewing the applicable regulatory text.

This map changes the buyer’s question from:

Is this phthalate still FDA authorized?

to:

Which exact authorization covers this phthalate in this component, at this use level, under these food-contact conditions?

A generic “FDA compliant” statement should not close approval unless it identifies the substance, material grade, packaging component, applicable provision, limitations, manufacturing source, and effective revision.

Which Parameters Determine Whether the Authorization Fits?

The same chemical can produce different regulatory and exposure decisions when its material or use conditions change.

Plasticizer Identity and Loading

Plasticizer identity determines which authorization must be used. Loading determines whether the formulation remains within any stated limit and also affects flexibility, seal compression, hardness, and migration potential.

A substitute with the same function does not inherit the previous material’s authorization or performance approval.

Polymer and Component Type

An authorization for an adhesive cannot automatically support use in a closure gasket. A provision covering PVC film cannot be applied to an unrelated coating or metallic-package lubricant.

The component determines:

• the applicable regulatory section;
• whether the substance contacts food directly;
• the relevant use-level calculation;
• which physical sample should be tested.

Food Type

Water content, fat content, acidity, and alcohol concentration can affect both authorization scope and migration behavior. This is especially important where the applicable provision expressly limits use to high-water-content, nonfatty, nonalcoholic, or defined FDA food categories.

Temperature and Contact Duration

Room-temperature storage, hot filling, retorting, reheating, and refrigerated use do not represent equivalent migration conditions.

Higher temperature or longer contact can increase transfer from the polymer into food or simulant. Evidence generated for refrigerated short-term contact should not be extended to hot-filled, fatty, or long-shelf-life applications without technical justification.

Thickness, Surface Area, and Package Geometry

Some provisions limit the thickness of the plasticized material. Package geometry also affects the ratio between food-contact surface and food quantity.

A result from a thick laboratory plaque or bulk compound may not represent migration from a thin commercial film, gasket, or coated surface.

Supplier, Grade, and Manufacturing Site

A CAS number does not define the complete commercial material. Plasticizer purity, additive package, formulation loading, polymer compatibility, process history, and manufacturing source can change the delivered material and its migration profile.

Supplier qualification must therefore attach approval to the commercial grade and source—not only the chemical name.

What Evidence Should Buyers Request?

Each document should answer one defined approval question.

What Can a COA Prove?

A batch-specific COA can show that the delivered lot meets listed release parameters. Depending on the component, these may include:

• plasticizer content;
• hardness or flexibility;
• thickness;
• density;
• appearance;
• coating weight;
• mechanical properties;
• another agreed batch-control variable.

The COA proves only what it measures.

It does not prove by itself:

• that every plasticizer has been disclosed;
• that the cited FDA authorization covers the intended use;
• that the package meets food-type, temperature, duration, or thickness limitations;
• that migration was evaluated;
• that the tested sample represents the converted package;
• that no supplier, site, or formulation change has occurred.

If phthalate identity or content is included on the COA, the result still needs a defined method and must be connected to the correct commercial lot.

How Should Phthalate Test Reports Be Compared?

Before comparing two laboratory results, check six variables.

1. Analyte Panel

A report covering DEHP and DINP does not establish the status of DCHP, DIOP, DIDP, BPBG, DEP, EPEG, or other plasticizers.

“Phthalates not detected” is not a complete result unless the report identifies which substances were tested.

2. Tested Object

The laboratory may have tested:

• neat plasticizer;
• polymer compound;
• film or sheet;
• adhesive;
• gasket or closure;
• finished package;
• food simulant or extract.

Results from different material states do not answer the same question.

3. Content Versus Migration

Solvent extraction followed by targeted chromatographic analysis can help identify or quantify plasticizers in a material. Migration testing measures transfer under defined contact conditions.

Material content may help confirm formulation identity or loading. It cannot replace migration evidence when the approval decision depends on transfer under the intended conditions.

Migration data cannot, in turn, prove that every plasticizer in the formulation has been identified.

4. Detection and Quantification Capability

Two laboratories may both report “ND” while using different analyte panels and reporting limits. A numerical result from a more sensitive method should not automatically be considered worse than “ND” from a less sensitive method.

FDA’s 2026 evaluation did not establish a new universal package-level phthalate limit. Buyers should therefore avoid inventing a pass/fail threshold from the evaluation itself.

5. Units and Reporting Basis

Check whether the result is reported by:

• mass of the tested component;
• mass of the finished package;
• surface area;
• volume of simulant;
• another calculation basis.

Results expressed in different units or against different physical objects should not be ranked without conversion and technical justification.

6. Sample and Batch Identity

The report should identify the material grade, component, batch, packaging revision, supplier, manufacturing site, sampling date, and test date.

An undated “typical report” can support preliminary screening but provides weak evidence for commercial approval.

When Is Commercial-Batch Validation Required?

A supplier sample can support further evaluation. It should not automatically qualify routine supply.

Commercial-batch validation is required when:

• the initial sample was laboratory-prepared;
• the plasticizer or additive package was provisional;
• the converter used noncommercial coating, lamination, curing, or sealing conditions;
• the final package uses different suppliers or manufacturing sites;
• the tested component changed before launch;
• the commercial grade cannot be tied to the qualification sample;
• a second source is replacing an approved material.

The preferred evidence chain is:

Supplier grade → Representative sample → Converter trial → Final package → First commercial lot → Routine release → Controlled change

Approval should stop if any link cannot be demonstrated.

When Should Supplier Requalification Be Triggered?

Requalification should be based on a change that can invalidate the existing evidence—not simply on the fact that FDA published an evaluation.

Reopen approval when there is a change to:

• plasticizer identity or loading;
• polymer grade or additive package;
• adhesive, coating, seal, liner, or closure construction;
• supplier or manufacturing site;
• converter or processing conditions;
• food type, alcohol or fat content;
• contact temperature or duration;
• material thickness or package geometry;
• analytical method or analyte panel;
• regulatory basis or customer specification.

A supplier change notification should identify the affected product, old and new state, effective date, technical reason, regulatory impact, supporting evidence, and commercial lots affected.

When Does the Recheck Become a Second-Source Decision?

Second-source qualification becomes appropriate when:

• the current supplier cannot identify the plasticizer;
• the authorization does not cover the intended application;
• migration evidence cannot support the actual use;
• a formulation must change to maintain supply;
• the supplier cannot provide revision or site traceability;
• customer restrictions require a different plasticizer or material;
• the current grade creates unacceptable regulatory-monitoring risk.

Do not compare replacement materials by CAS number, price, or general “non-phthalate” status alone.

Compare:

Authorization scope + Plasticizer loading + Polymer compatibility + Flexibility or seal performance + Migration evidence + Extractables or odor risk + Commercial source + Batch control + Change notification

A replacement can pass regulatory screening but fail converting or package performance. Changes in plasticizer chemistry can alter flexibility, hardness, seal compression, low-temperature behavior, bleed or bloom, adhesion, odor, and extraction behavior.

The second source should therefore pass both regulatory-scope review and application validation before commercial approval.

Final Approval Decision

Retain approval only when:

• the current commercial construction is defined;
• every relevant plasticized component is mapped;
• the exact phthalate identity is known;
• the cited authorization matches the component and intended use;
• use level, food type, temperature, duration, and material dimensions remain inside the applicable conditions;
• analytical reports use an adequate scope and represent the commercial package;
• the first commercial lot is connected to the qualified sample;
• supplier, site, formulation, and package changes are controlled.

Keep approval open when any of these relationships is missing.

If the gap is documentary, request an updated regulatory statement, formulation declaration, or source-specific evidence. If the gap is analytical, define the test object, analytes, reporting capability, and intended-use conditions before ordering testing.

If the recheck identifies a need for an alternative plasticizer, polymer additive raw material, or second source, review ChemicalCell’s polymer additive raw-material capabilities. For a specification or sample discussion, submit the chemical identity, polymer system, packaging component, function, current loading, intended food-contact conditions, required documentation, sample quantity, commercial volume, and change-control requirements through the ChemicalCell RFQ form.

ChemicalCell can review available material specifications, COA/SDS/TDS support, samples, and commercial supply options. Final food-contact suitability must remain tied to the exact grade, supplier, package construction, intended use, and applicable FDA authorization.